BRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide API

Reuters11-19

BRIEF-<a href="https://laohu8.com/S/688117">Chengdu Sheng Nuo Biotec</a> Says Unit Gets Regulatory Approval For Visepegenatide API

Nov 19 (Reuters) - ChengDu Sheng Nuo Biotec Co Ltd 688117.SS:

SAYS UNIT RECEIVES APPROVAL FROM CHINESE MEDICAL REGULATOR FOR ITS VISEPEGENATIDE ACTIVE PHARMACEUTICAL INGREDIENT TO ENTER MARKET

Source text

Further company coverage: 688117.SS

(Reporting by Beijing Newsroom)

((Ethan.Wang@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584915083?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584915083","market":"nz","top_or_hot":-1,"title":"BRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide API","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/688117\">Chengdu Sheng Nuo Biotec</a> Says Unit Gets Regulatory Approval For Visepegenatide API</title></head><body><p><span>Nov 19 (Reuters)</span><span> - </span>ChengDu Sheng Nuo Biotec Co Ltd <span>688117.SS</span>:</p><ul><li><p>SAYS UNIT RECEIVES APPROVAL FROM CHINESE MEDICAL REGULATOR FOR ITS VISEPEGENATIDE ACTIVE PHARMACEUTICAL INGREDIENT TO ENTER MARKET</p></li></ul><p>Source text</p><p>Further company coverage: <span>688117.SS</span></p><p> (Reporting by Beijing Newsroom)</p><p> ((Ethan.Wang@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide API\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/688117\">Chengdu Sheng Nuo Biotec</a> Says Unit Gets Regulatory Approval For Visepegenatide API</title></head><body><p><span>Nov 19 (Reuters)</span><span> - </span>ChengDu Sheng Nuo Biotec Co Ltd <span>688117.SS</span>:</p><ul><li><p>SAYS UNIT RECEIVES APPROVAL FROM CHINESE MEDICAL REGULATOR FOR ITS VISEPEGENATIDE ACTIVE PHARMACEUTICAL INGREDIENT TO ENTER MARKET</p></li></ul><p>Source text</p><p>Further company coverage: <span>688117.SS</span></p><p> (Reporting by Beijing Newsroom)</p><p> ((Ethan.Wang@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0K9:1","article_id":"2584915083","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584915083","pubTimestamp":1763539645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide APINov 19  - ChengDu Sheng Nuo Biotec Co Ltd 688117.SS:SAYS UNIT RECEIVES APPROVAL FROM CHINESE MEDICAL REGULATOR FOR ITS VISEPEGENATIDE ACTIVE PHARMACEUTICAL INGREDIENT TO ENTER MARKETSource textFurther company coverage: 688117.SS  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688117":"圣诺生物","BK0239":"医药制造"},"translate_title":"简介-成都盛诺生物科技表示，维培根肽API获得监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688117":0.9},"content_text":"BRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide APINov 19 (Reuters) - ChengDu Sheng Nuo Biotec Co Ltd 688117.SS:SAYS UNIT RECEIVES APPROVAL FROM CHINESE MEDICAL REGULATOR FOR ITS VISEPEGENATIDE ACTIVE PHARMACEUTICAL INGREDIENT TO ENTER MARKETSource textFurther company coverage: 688117.SS (Reporting by Beijing Newsroom) ((Ethan.Wang@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584915083","isCrawlerRequest":true}